ICI-Based Urologic Cancer Therapies Tied to High Adverse Event Rates
Urologic cancer treatments based on immune checkpoint inhibitors are associated with a high incidence of treatment- and immune-related adverse events.
Source: empr.com
Stay updated with breaking news from Mingmin Li. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Urologic cancer treatments based on immune checkpoint inhibitors are associated with a high incidence of treatment- and immune-related adverse events.
Urologic cancer treatments based on immune checkpoint inhibitors are associated with a high incidence of treatment- and immune-related adverse events.